TAPERANK
Open the app
MOVER · FRI OCT 23 2026

Why SPRC rose 26.6% on Oct 23 2026: clinical trial progress

SPRC+26.6%on Fri Oct 23 2026

SciSparc Ltd. Ordinary Shares was up 26.6% on the day at $1.52, ranked #2 on 1178× its usual five-minute volume, when TapeRank recorded this spike at 18:02 ET during after hours.

THE DAY ON THE LIST · 1 EVENT

  1. 18:02 ET
    MOVER · AFTER-HOURS

    $1.52 · ▲ 26.6% ON THE DAY · 1178× 5M RVOL · RANK #2

    STRETCHEDCONFIDENCE4/5

    SPRC rose 20% on the day and accelerated another 5.11% in five minutes after reporting positive progress in an FDA-approved Phase IIb Tourette syndrome trial. The update is a clinical-progress headline without disclosed efficacy data, regulatory approval, or quantified commercial impact, while the cited F-3 registrations create share-issuance risk into the move.

    WHYA 20% move on positive but unquantified Phase IIb progress is materially larger than the disclosed news supports, with only 566K shares outstanding amplifying order flow.
    ANALYZED 17:59 ET · 2 MIN AGO · OPENAI/GPT-5.6-LUNA
    THE ROW AND SESSION LEVELS AT 18:02 ET
    LAST1.52
    DAY▲ 26.6%
    5 MIN▲ 5.54%
    5M RVOL1178×
    5M $VOL$502K
    FLOAT*566K
    RANK#2
    SESSIONAFTER-HOURS
    VWAP1.37
    HOD1.57
    LOD1.06
    OR HIGH1.21
    OR LOW1.10
    PREV CLOSE1.20
    PM HIGH1.41
    PM LOW1.18
    GAP▲ 0.83%

    * FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE

THE SESSION

  • 09:30 ETOpened at $1.21, +0.8% on the previous close of $1.20
  • 09:30 ETRegular-session high, $1.21
  • 14:47 ETRegular-session low, $1.07
  • 15:59 ETLast trade of the regular session, $1.08, -10.0% on the previous close of $1.20
  • Volume: 100K shares in regular hours, 95K before the open

SPRC opened at $1.21, briefly matching its high, then declined through the regular session to a $1.07 low before ending at $1.08, down 10.0% from the previous close. After the close, TapeRank recorded the stock at $1.52 and rank #2; its read tied the move to positive progress in an FDA-approved Phase IIb Tourette syndrome trial, while noting the update included no efficacy data, regulatory approval, or quantified commercial impact and that F-3 registrations created share-issuance risk. TapeRank found no halts during the session.

WRITTEN FRI OCT 23 2026 20:00 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE

FILINGS AND NEWS · 24H BEFORE THE MOVE

On the tape right now

WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY

01
ECGSURGING 0:05
79.71
▼ 29.3%
▼ 1.41%
41.0×
FAD
$6.2M
51.1M*
STRETCHED
02
CAVASURGING 0:00
64.78
▲ 7.4%
▲ 1.30%
9.3×
ORBHODVWH
$11.6M
116.8M*
UNEXPLAINED
03
URGNSURGING 0:00
29.16
▼ 15.2%
▼ 1.29%
15.6×
FAD
$1.4M
48.9M*
JUSTIFIED
04
MPTISURGING 0:00
64.15
▼ 1.5%
▲ 0.96%
23.8×
VWH
$637K
4.3M*
UNEXPLAINED
05
LSPDSURGING 0:00
11.52
▲ 4.9%
▼ 1.24%
16.5×
ORB
$426K
133.3M*
UNEXPLAINED
06
CRCTSURGING 0:00
8.90
▲ 49.2%
▼ 0.72%
15.1×
GAPORBVWHEXT
$395K
54.7M*
STRETCHED
07
BROSSURGING 0:00
43.97
▲ 0.9%
▼ 0.91%
4.0×
FAD
$4.3M
137.9M*
UNEXPLAINED
08
LMRICOOLING 1:35
12.85
▲ 14.5%
▲ 1.06%
132×
ORBHODVWH
$1.7M
—
UNEXPLAINED
Open the full list